Tissue Memory Score captures proximal tubular identity loss and independently stratifies survival in clear cell renal cell carcinoma.
A tissue memory score independently predicts survival in kidney cancer and improves risk assessment beyond standard staging in multiple patient cohorts.
TMS independently associates with OS in ccRCC (HR 0.595/SD; P=6.6e-5), improves discrimination over stage (delta-C-index 0.0189), replicates in two external cohorts, and separates 5-year survival by 17.3 pp by TMS tertile in stage II-III disease. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- Multi-cohort retrospective validation (TCGA-KIRC n=540; CPTAC-3 and E-MTAB-1980 external cohorts; random-effects meta-analysis)
- Category
- sentinel_scan
- Maturity
- Validated
- Journal
- Urologic Oncology
Why it surfaced
Novel biologically anchored prognostic biomarker with three-cohort external validation for the most common kidney cancer; platform-robust and ready for prospective evaluation; directly actionable for risk stratification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.